Balakrishna B.,Agricultural College |
Reddy V.C.,Agricultural College |
Ahamed M.L.,Agricultural College
Indian Journal of Ecology | Year: 2016
Substantial variation for fibre quality traits is known to exist in Gossypium barbadense. Multivariate analysis employing Mahalanobis D2 analysis classified the twenty genotypes into seven clusters. Cluster II was the largest consisting of six genotypes followed by cluster I and cluster IV with five genotypes each. The inter cluster distances were maximum when compared to intra-cluster distances, indicated presence of wide genetic diversity among the genotypes of different clusters than those of same cluster. The hybridisation programme with parents selected by considering inter cluster distances may produce high magnitude of heterosis or desirable segregants, which would be meaningful for improvement in yield and quality attributes of cotton.
News Article | May 16, 2017
News selected on topics and regions - oil and gas, business, politics, IT, the South Caucasus, the Caspian Sea region, Central Asia Ranking of the Azerbaijani banking sector The OSCE Centre in Ashgabat organized a study visit to Vienna for representatives of the Turkmen State Energy Institute in Mary in order to show them international best practices in the field of renewable energy sources usage, said the OSCE in a message posted on its website. During the visit, the Turkmen delegation visited the Agricultural College Tulln and the Energiepark Bruck/Leitha complex, which generates electricity from wind and solar energy, as well as a biogas plant at the same location, says the message.
News Article | May 23, 2017
FORT COLLINS, Colo.--(BUSINESS WIRE)--Colorado State University’s Flint Animal Cancer Center and Synaptive Medical Inc. are collaborating to develop an intraoperative imaging and sensing technology to more accurately detect and treat brain tumors. Dr. Rebecca Packer, an associate professor of neurology and neurosurgery at Colorado State University, is the first neurosurgeon in the world to use Synaptive’s Raman spectroscopy research system to explore clinical biomarkers that can assist in surgical resection of tumors. The system also improves the preservation of normal brain tissue. Dr. Packer's research focuses on developing novel therapies for brain tumors while advancing precision medicine and innovation for humans and veterinary patients. Her ultimate goal? To develop accurate and less invasive neurosurgical techniques and therapies to treat brain tumors, in part by improving intraoperative imaging to more accurately detect and resect tumors during surgery. Intraoperative means occurring or performed during surgery. CSU's veterinarians, clinicians and staff are firm believers in the One Health Initiative approach to cancer research, in which veterinary and human medicine share a common goal. This is also known as comparative oncology. “There are many similarities between canine and human brain tumors," said Dr. Packer. "As such, knowledge gained from clinical trials in our veterinary brain tumor patients may also help advance therapies for humans.” Synaptive Medical is undertaking collaborative efforts to interconnect and optimize the secure flow of imaging and non-imaging data while integrating it into existing surgical technologies. “Novel sensing technologies would support a surgeon when she is performing a procedure and when rapid clinical decisions need to be made,” said Cameron Piron, Synaptive’s president and co-founder. “The Flint Animal Cancer Center is among the best in the world for the prevention, diagnosis and treatment of cancer in pet animals, and this is a natural collaboration for us to advance both veterinary and human neurosurgery.” The incidence of a recurrent brain tumor in humans remains high and researchers believe it could be minimized with greater levels of resection. Some brain tumors are so visually like normal brain tissue that differentiation is challenging, particularly when removing adjacent healthy tissue could compromise brain function. “Surgeons tell us they would rather leave a residual tumor because the risk of neurological deficit outweighs the benefit,” said Piron. “Improving the accuracy of surgical intervention is critical.” Through a generous donation from the Eldred Foundation, the CSU College of Veterinary Medicine and Biomedical Sciences is the first to acquire Synaptive’s research system. Raman spectroscopy is a rapid and powerful imaging technique that has been extensively used in other scientific disciplines to understand the chemical composition of tissue. Currently, no hand-held system can rapidly detect tumor tissue. CSU’s initial research goal is to confirm the specific spectral “fingerprint” of the various brain tumor types, and match that fingerprint with the microscopic appearance of the tumor and surrounding normal tissue. “We expect that, ultimately, this technology will make the surgical resection of brain tumors safer and more accurate, but given the advancements in tumor vaccines and immunotherapies, it is reasonable to speculate that one day a device might even allow us to obtain a diagnosis and determine optimal patient-specific treatments without the need for invasive surgery,” said Dr. Packer. Synaptive Medical’s current surgical solution, BrightMatter™, supports a patient-centric, scalable model that is automated for surgical planning and intervention with visualization of a patient’s unique fiber tracts, state-of-the-art optics for workflow efficiencies and recent FDA-cleared health informatics. “We aim to accelerate value-based care by providing more precise information to surgeons during surgical procedures, giving them more real-time information with which to make the best possible decisions for their patients,” said Piron. Learn more about brain tumors in pets and Dr. Packer's work and research. About Colorado State University: Founded in 1870 as the Colorado Agricultural College, CSU is now among the nation's leading research universities. Located in Fort Collins, CSU currently enrolls more than 33,000 students, and has more than 1,800 faculty members working in eight colleges. CSU is recognized as a premier research institution and routinely ranks as one of the top American universities without a medical school in research expenditures. In Fiscal Year 2016, CSU research expenditures totaled $332 million; this was the ninth consecutive year research expenditures at the university have topped $300 million. More information is available at www.colostate.edu. About the Flint Animal Cancer Center | The Colorado State University Flint Animal Cancer Center is a preeminent cancer center for animals, and offers the latest in diagnostics and treatment for all kinds of cancer in companion animals including surgery, chemotherapy and radiation therapy. About Synaptive Medical | Synaptive Medical Inc., a Toronto-based medical device and technology company, collaborates with leading clinicians and healthcare systems to revolutionize products and services that cross traditional barriers to enable continuous improvement in care delivery in and beyond the operating room. Synaptive’s integrated BrightMatter™ solutions — including surgical planning, navigation and visualization, and an informatics platform — are designed to give clinicians the right information they need to ensure the best possible outcomes for patients.
News Article | May 24, 2017
FORT COLLINS, Colorado--(BUSINESS WIRE)--Le Flint Animal Cancer Center de l'Université d'État du Colorado (CSU) et Synaptive Medical Inc. collaborent pour développer une technologie d'imagerie et de détection peropératoire pour détecter et traiter les tumeurs cérébrales de manière plus précise. Les recherches du Dr Packer sont concentrées sur le développement de thérapies innovantes pour lutter contre les tumeurs cérébrales, tout en faisant progresser la médecine de précision et l'innovation pour les patients humains et vétérinaires. Son objectif ultime? Développer des techniques et des thérapies neurochirurgicales précises et moins invasives pour traiter les tumeurs cérébrales, en améliorant en partie l'imagerie peropératoire pour détecter et réséquer avec plus de précision les tumeurs pendant une intervention. Peropératoire signifie qui se produit ou est réalisé durant une intervention chirurgicale. Les vétérinaires, les médecins et le personnel de la CSU croient fermement en l'approche One Health Initiative en matière de recherche contre le cancer, dans laquelle la médecine vétérinaire et humaine partage un rôle commun. Cette approche est également connue sous le nom d'oncologie comparative. Synaptive Medical entreprend des efforts collaboratifs pour interconnecter et optimiser le flux sécurisé de données d'imageries et autres, tout en l'intégrant aux technologies chirurgicales existantes. "Les technologies de détection innovantes pourraient épauler un chirurgien lorsqu'il est en intervention ou lorsque des décisions cliniques doivent être prises rapidement", déclare Cameron Piron, président et cofondateur de Synaptive. "Le Flint Animal Cancer Center fait partie des meilleurs centres au monde pour la prévention, le diagnostic et le traitement du cancer chez les animaux de compagnie. Cette collaboration en vue de faire progresser la neurochirurgie vétérinaire et humaine est toute naturelle pour nous." Grâce à un don généreux de l'Eldred Foundation, le Collège de médecine vétérinaire et des sciences biomédicales de la CSU est le premier à acquérir le système de recherche de Synaptive. La spectroscopie Raman est une technique d'imagerie rapide et efficace qui a été largement utilisée dans d'autres disciplines scientifiques pour comprendre la composition chimique des tissus. À l'heure actuelle, aucun système portable ne peut détecter rapidement les tissus tumoraux. L'objectif initial des recherches de la CSU est de confirmer l'empreinte spectrale spécifique des divers types de tumeurs cérébrales, et de la mettre en correspondance avec l'apparence microscopique de la tumeur et des tissus environnants normaux. "Nous espérons qu'au final cette technologie rendra la résection chirurgicale des tumeurs cérébrales plus sûre et plus précise, mais avec les progrès réalisés dans les vaccins tumoraux et les immunothérapies, il est raisonnable d'envisager qu'un jour un dispositif pourrait même nous permettre d'obtenir un diagnostic et de déterminer un traitement optimal pour un patient particulier sans avoir recours à la chirurgie invasive", ajoute Dr Packer. Cliquez ici pour en savoir plus sur les tumeurs cérébrales chez les animaux de compagnie et sur le travail et les recherches du Dr Packer. À propos de l'Université d'État du Colorado: Créée en 1870 sous le nom de Colorado Agricultural College, la CSU fait aujourd'hui partie des principales universités de recherche du pays. Située à Fort Collins, la CSU accueille plus de 33 000 étudiants, et emploie plus de 1 800 membres du personnel enseignant dans huit campus. À propos de Synaptive Medical | Basée à Toronto, Synaptive Medical Inc., est une société spécialisée dans les technologies et équipements médicaux. Synaptive collabore avec des cliniciens et des systèmes de santé de renom pour dépasser les obstacles traditionnels et permettre une amélioration continue en matière de soins de santé, aussi bien au bloc opératoire qu’en dehors. Les solutions intégrées BrightMatter™, qui comprennent la planification, la navigation et la visualisation chirurgicales, la robotique et une plateforme informatique intégrée, sont conçues et fabriquées pour donner aux cliniciens les informations nécessaires pour garantir les meilleurs résultats possibles pour les patients.
News Article | December 6, 2016
Symbios Technologies, Inc., a world-leading developer of dynamic aqueous plasma technology platforms, announced today that the company has engaged in a collaborative research partnership with Colorado State University (CSU) through a five-year Master Research and Development Agreement (MRDA) with the CSU Office of the Vice President for Research. This agreement is designed to further the commercialization of the company’s technology and the mission of CSU as a modern land-grant university. The MRDA outlines the working relationship between Symbios and CSU’s world-renowned programs in agriculture, engineering, veterinary medicine, biomedical sciences, chemistry, oncology, biology, and many other disciplines that have established CSU as an international academic and research leader. Through the MRDA, Symbios has sponsored research agreements, technology transfer, and joint intellectual property development via faculty collaborations and employment. Currently, Symbios is collaborating with CSU's Dr. Douglas Thamm, professor of Oncology and director of Clinical Research at the CSU Flint Animal Cancer Center. Dr. Thamm, a veterinary oncologist, is a consultant on Symbios' current National Institutes of Health (NIH) grant from the National Cancer Institute. In addition, Symbios engaged CSU graduate Jessica Joslin, who has a doctorate in physical chemistry, as a National Science Foundation (NSF) postdoctoral fellow. Joslin was subsequently hired as the company’s senior scientist and serves as the principal investigator on two NIH grants in collaboration with CSU. Through the partnership, Symbios has provided multiple internships to CSU engineering students; James McCall was recently hired as the company’s chemical & biological engineer. CSU also hosts Symbios as one of the companies in residence at the CSU Research Innovation Center at the Infectious Disease Research Center on the Foothills Campus, further facilitating contracts with multiple laboratories and manufacturing facilities on campus. “The Office of the Vice President for Research helps fulfill the land-grant mission of CSU by fostering and supporting the research enterprise, promoting scholarship and artistry, instilling a culture of integrity, and capitalizing on opportunities to address global challenges,” said Mark Wdowik, assistant vice president for Research & Industry Partnerships. “The collaboration with Symbios has resulted in a significant investment in CSU research. We anticipate many times that level of engagement, as well as possible licensing of CSU and jointly-developed technologies, as part of Symbios' ongoing collaborations with CSU faculty and students, centers and startup companies, and other private and public partners.” Justin Bzdek, Symbios president & CEO, said, “CSU has been an outstanding resource to help Symbios commercialize our groundbreaking plasma technology. This agreement will help facilitate further collaborative work with the CSU Flint Animal Cancer Center as well as other research faculty who can utilize our low-power, continuous flow plasma technology to develop applications to treat some of the most difficult to remediate industrial processes and wastewater and generate advanced chemotherapeutics and anti-infective products to reduce the global impact of deadly diseases.” Alan Rudolph, vice president for Research at CSU, also hailed this partnership. “Collaborative research relationships like the one with Symbios play a critical role in driving innovations from laboratories to the marketplace," he said. "As companies seek new product pipelines, more of them are turning to CSU, which is well-known for its core technical and research and development strengths, its ability to solve today’s complex problems across a broad range of industries, and its capabilities to provide independent, third-party assessments.” Symbios Technologies, Inc. is a world-leading developer of dynamic aqueous plasma technology platforms for water treatment, specialty manufacturing, and biotherapeutic applications. The company, working with its university, government, and industrial partners, is commercializing its disruptive advanced low-cost aqueous plasma oxidation technology, the Symbios Tubular Plasma Reactor™ (TPR4000™), to clean water, preserve the environment, and protect human health while improving production economics and sustainability. Symbios Technologies’ modular reactor is low in capital cost, able to replace existing energy-hungry or poor-performing advanced oxidation processes, while reducing or eliminating the use of biocides and/or chemical additives, thus improving the overall maintenance cost of water treatment systems. The TPR4000 also has the potential to generate less toxic chemotherapy drugs and safer anti-infectives to reduce the global impact of deadly diseases. For more information, go to http://www.symbiosplasma.com/. Founded in 1870 as the Colorado Agricultural College, Colorado State University is now among the nation's leading research universities. Located in Fort Collins, CSU currently enrolls more than 33,000 students, and has more than 1,800 faculty members working in eight colleges. Colorado State University is recognized as a premier research institution and routinely ranks as one of the top American universities without a medical school in research expenditures. In Fiscal Year 2016, CSU research expenditures totaled $332 million; this was the ninth consecutive year research expenditures at the university have topped $300 million. More information is available at http://www.colostate.edu. The IDRC provides a secure, state-of-the-art facility for university investigators, government scientists, and industry representatives to collaboratively research the basic biology, biochemistry, molecular biology, and epidemiology of bacteria and viruses that cause human and animal diseases. The Center provides a research environment for developing new scientific discoveries, vaccines, methods of diagnosis, and therapeutic agents for infectious agents. The CSU Research Innovation Center is a 72,000 sq. ft. research center that fosters private and public sector collaboration. The CSU Bioscience Business Incubator, located within the Research Innovation Center, is aligned with the mission of the University to provide a return on public investment in research by generating economic opportunities through new companies focused on problems or issues of public interest.
News Article | November 22, 2016
ELANORA-GOLD COAST, AUSTRALIA, November 22, 2016-- Professor Dr. Henry O Meissner (also known in earlier years of his career under full name Ostrowski-Meissner) has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Professor Dr. Meissner is a three-time graduate of the Agricultural University of Kraków, from which he holds a Ph.D. in nutritional biochemistry, a Master of Science in environmental physiology, and a Bachelor of Science in agricultural sciences. For more than five decades, he has utilized his educational foundation in his career as a nutritional biochemist and educator. Professor Dr. Meissner has devoted his work to the prevention and intervention of metabolic and medical conditions through standardized bioavailable herbal therapeutic products, non-invasive therapies and functional health foods, with special consideration to environmental and ecological factors. He is noted for his research in all aspects of nutritional biochemistry and manufacturing technology of herbal extracts, as well as herbal extraction technology and application of standardized herbal extracts in dietary and therapeutic practice. His work has led to the development of production lines and a variety of unique proprietary therapeutic and functional products for different companies in Australia and internationally.Since 1986, Professor Dr. Meissner has served as the executive director of research and development for TTD International. The company, which is primarily concerned with natural health services and food technology, supports his efforts to create preventive and therapeutic programs for specific groups of people, such as diabetics, athletes, the overweight, those with celiac disease and women with pre- & post-menopausal symptoms. Professor Dr. Meissner has developed and introduced to the international market a variety of novel functional foods, therapeutic preparations, raw standardized active herbal ingredients, and ready-to-use dietary supplements and therapeutics derived through non-chemical extraction of freshly-harvested biomass of organically-cultivated medicinal plants.Passionate about environmental pollution caused by plastic waste, Professor Dr. Meissner spent about 10 years on applied research related to biodegradable polymers used as packaging material, including potable water, various liquids, and dried and fresh food. He also involved himself in the study and introduction of electro-chemically activated, non-toxic water sanitizer for use in public and commercial facilities as a non-toxic disinfectant for processing equipment, as well as a preservative for fresh foods and non-chemical sanitizer for pure and contaminant-free communal water supply. Further achievements include designing an environmentally friendly, solar-powered bio-sanitation system for the delivery of potable water through purification using non-chemical disinfecting sanitation of contaminated water sources. The water is delivered in various biodegradable flexible plastic packaging forms to communities in need of pure water and medical intervention in locations worldwide. Additionally, as an extension to his work in therapeutic research, Professor Dr. Meissner has designed and introduced to the market therapeutic devices for personal use, such as a hand-held multi-channel personal pulse magnetic device and personal dual photo-spectral device for dermal regeneration.Professor Dr. Meissner has parlayed his knowledge into a number of research and teaching positions over the years, including at Sydney University, CSIRO-Australia, Nagoya University in Japan, Hubei Agricultural College in China, the Chinese Academy of Science (both Agricultural and then Medical Sciences), Charles Sturt University in Bathurst, NSW, Australia and Research Institute of Medicinal Plants in Poland. He has also held leadership, international research coordinator and consultant roles with a multitude of organizations and institutions nationwide. Professor Dr. Meissner has authored 23 books and contributed more than 300 articles to professional journals. His many accomplishments were taken into consideration when he was chosen to be featured in the 2nd through 8th editions of Who's Who in Medicine and Healthcare, as well as several editions of Who's Who in the World and Who's Who in Science and Engineering.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis now publishes many Who's Who titles, including Who's Who in America , Who's Who in the World , Who's Who in American Law , Who's Who in Medicine and Healthcare , Who's Who in Science and Engineering , and Who's Who in Asia . Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com
News Article | October 28, 2016
Two brothers had dramatic career changes and moved home to continue the family blacksmith trade – by creating 3D metal signs and pieces of art. Luke Markey had a high-flying job as a forensic accountant consulting for top companies around the world while brother, Neil, completed three tours of duty with the U.S. Army in Iraq and Afghanistan But both Luke and Neil eventually realised their destiny was to work with their father Peter, a modern-day blacksmith who helped build the gates at the Statue of Liberty. The three men now make large 3D metal signs for top brands and organizations – including the University of Maryland – and complex metal works of art from their forgery in Frederick, Maryland. Luke said it took a while to learn the trade – but that the businesses have become unstoppable with both his brother and father on board. He said: ‘In the beginning I spent a lot of time on the forge, just swinging the hammer.’It felt great. I remember one Friday night asking my dad to teach me some things, and there we were from 7pm until 11pm working side by side..’ Luke and Neil’s success story stretches back almost five generations. Their great-great-great-great uncle was known for his handcrafted intricate iron work and by the end of his life he had made three stoves each worth the value of a home. While their great-great-great- grandmother’s hand-woven quilts are still on display today in the Daughters of the American Revolution museum in Sussex, New Jersey. Luke said that as children both he and Neil spent countless hours with their father in the family shop watching him work and absorbing the art. Neil also felt that continuing the family tradition was his calling in life. He studied mathematics at the University of Maryland then joined the Army in 2003 after the invasion of Iraq. Neil led an Infantry platoon from the Fourth Infantry Division and deployed to Iraq in 2008. Neil was later assigned to the US Army Special Operations Command, with the Second Ranger Battalion, and completed two more tours to Afghanistan. But after leaving the Army Neil also moved to the East Coast to complete an MBA at Columbia University. Outside school he travelled home often and the brothers experimented together with their father. They developed a unique method of turning simple two-dimensional logos and images into three dimensions using metal as their medium. Their first prototype was of the Baltimore Oriole, which weighed nearly 20 pounds with ugly jagged lines and assembly. The piece also inspired the name ‘shield’ which Luke and Neil decided would be the name for their company. They now keep the piece on the wall of their workshop to show how far the company has developed. Their first finished metal signage pieces were for the Rangers, a 3D representation of the Ranger scroll. The scroll is worn on the right sleeve only by members of the elite unit who have completed a deployment. Neil said: ‘The scrolls were great practice for us and we donated the profits back to the Pointe du Hoc Foundation.’ After refining their metal crafting success, orders began to increase. They recently released a beautiful, brushed stainless steel, three-dimensional version of the beloved Frederick skyline. They drew the inspiration from a similar piece of art created by their father and uncle Richard years ago. Next, after receiving NCAA licensing approval in July 2014, they created a beautiful piece for the University of Maryland; a representation of the beloved ‘Terrapin’, the school’s mascot. It also serves as tribute to their great-great grandfather, D. John Markey, a World War Two veteran and the first head football coach for the University of Maryland, originally named Maryland Agricultural College, in 1902. Later, they worked with the University of Maryland ROTC program to design a custom 3D signage piece for their new facilities. The brothers also create custom pieces and have made high-quality versions of business logos for display in offices and entrances. They sold their first piece to the Director of the Lang Entrepreneurship Center at Columbia Business School. It is proudly displayed at the entrance of his energy consultancy firm in New York City. They have worked with major organizations like the National Association of Relators – turning their 2D logo into a 3D piece of art. ShieldCo is now focusing their efforts on custom signage design for businesses and organizations. They are currently working on a design for Ferrari – for the company and its fans. Neil said: ‘Every detail was carefully thought through. The design is laser cut to a precision of 1/1000 of an inch. Exposed bolts on the piece give it a feeling of toughness and match the lug nuts on a Ferrari wheel.’ The company also supports the Pointe du Hoc Foundation, which Neil helped form in 2010 while serving with the Rangers. The Foundation recently completed a beautiful memorial this year in Washington State; a tribute to all the Rangers killed in action. Neil drew the initial design by hand.
News Article | November 15, 2016
Nova Scotia-based cricket farm set to become a leading provider of sustainable alternative protein for pet food products MISSISSAUGA, ON--(Marketwired - November 15, 2016) - Dane Creek Capital Corp. ('DCCC' or the 'Company'), a merchant banking venture that focuses on pet industry investments, is pleased to announce it has acquired a 48% interest in Midgard Insect Farm Inc. ('Midgard'), a cricket producer headquartered in Windsor, Nova Scotia. Midgard crickets are a featured ingredient in the Company's Dockside brand of planet friendly pet treats, meal mixers, and meal toppers for dogs and cats created using ingredients from rescued fresh food and sustainable sources. DCCC's investment will also facilitate research and development aimed at growing Midgard's business to become a leading wholesaler to pet industry companies looking to incorporate insect protein into their products. Midgard is one of a growing number of companies raising insects as an alternative and sustainable source of protein for both human and animal consumption. Whereas cricket farms have traditionally focused on the sale of live crickets for pet specialty retail, Midgard's model will focus exclusively on the production of whole ground cricket meal to satisfy growing demand for alternative proteins in the pet food industry. Over the course of the next 18 months, the Company expects the expansion of Midgard's production capacity and ancillary operations will generate up to 15 new jobs for the local economy. Midgard was founded and is currently operated by Joy Hillier, a registered veterinary technician and graduate of Dalhousie University's Agricultural College whose interest in food security and sustainability led to her interest in edible insects. She also has professional experience in the food industry, animal husbandry, biosecurity technology, and laboratory procedure. Through her partnership with DCCC, Hillier joins the ranks of women entrepreneurs closing the gender gap on securing capital investment in North America. Studies indicate only 10% of venture capital has been allotted to female founded startups spanning back to 2010 of which those in science and technology are particularly challenged. "We are very pleased to be making this announcement," says Mark Warren, Chairman & CEO of DCCC. "We recognised early on it would be important for us to vertically integrate our sources of sustainable ingredients for the Dockside brand of pet products. Additionally, as sustainability becomes a leading concern among pet owners, we believe there will be opportunities to expand the business to provide cricket protein to the pet industry as a whole. We were very impressed with Joy and her unique blend of scientific curiosity and entrepreneurial savvy and are excited to be given this opportunity to help her grow her business." An immediate result of the partnership will be the establishment of a 1,500 square foot research facility for Midgard in association with Perennia, a non-profit corporation in Bible Hill, Nova Scotia dedicated to helping the province's farmers, fishers, and food processors prosper. This second Midgard location will allow Hillier to work closely with Perennia's team of food research scientists and nutritionists to produce top quality cricket meal with an initial focus on consistency, an issue which has challenged the industry. The collaboration marks an extension of the Company's existing relationship with Perennia involving ongoing research and development into Dockside sustainable pet food products. "I am very excited to welcome Dane Creek as an equity partner in my venture," says Hillier. "Their support for my vision coupled with their pet industry and business management expertise will allow me to focus my time and energy on the developing science of cricket production and creating a high quality product for the pet food industry that will improve its sustainability as a whole. They will also be a valuable asset as we look to increase production and start hiring and training new personnel over the next year." Crickets as an alternative protein source offer both environmental and nutritional benefits. According to the Food & Agriculture Organization of the United Nations, crickets are twice as efficient as chicken and six times more efficient than cattle at converting feed to protein. They also consume far less water, approximately 1/2000th the volume required to produce the same amount of beef, and require less space. Nutritionally, crickets provide an easily digestible protein and a complete source of all the essential amino acids dogs and cats require, including taurine. They also provide calcium, omega-3 fatty acids, and prebiotic chitin, and contain higher levels of iron and magnesium than beef on a pound for pound basis. Negotiations between DCCC and Midgard were facilitated by Perennia, the Atlantic Canada Opportunities Agency, and Nova Scotia Business Inc., a private-sector business development agency. DCCC's equity stake is held by Dockside Investco, its wholly owned holding company in Nova Scotia. Financial terms were not announced. With over 30 years of experience in the pet industry and an extensive network of industry professionals, we offer valuable financial and management support to up-and-coming companies in the companion animal sector through selective, strategic investments. Our investment horizon is long-term taking into account current trends and changes in pet owner demographics with a current focus on opportunities in pet food products sourced from sustainable ingredients, alternative models for veterinary care, biotechnology, pet insurance, pet hotels, and pet-related technological applications for pet owners.
News Article | November 17, 2016
Nova Scotia-Based Cricket Farm Awarded by Atlantic Canada Opportunities Agency and Innovacorp for Its Innovative Startup Model WINDSOR, NS--(Marketwired - November 17, 2016) - Midgard Insect Farm Inc. ("Midgard" or the "Company") is pleased to announce it has been chosen as one of the winners of the 2016 Spark West Innovation Challenge ("Spark West"). Established in February of this year, Midgard is on course to become a leading supplier of high-protein cricket meal to the pet food industry as a sustainable and nutritious alternative to traditional protein sources. Midgard was founded and is currently operated by Joy Hillier, a graduate of Dalhousie University's Agricultural College. Her idea to pursue the cultivation of edible insects was born of a keen interest in food security and environmental sustainability coupled with previous experience in the food industry, animal husbandry, biosecurity technology, and laboratory procedure. She recently sold a 48 percent stake in Midgard to Dane Creek Capital Corp., a merchant banking venture which focuses on pet industry investments. Hillier continues to own the remaining 52 percent. Spark West is presented by the Atlantic Canada Opportunities Agency and Innovacorp. The first annual competition supports startups in the province with a focus on innovators in information technology, life sciences, clean technology and ocean technology sectors. "We introduced Spark West after four rounds of a similar competition in Cape Breton," said Stephen Duff, president and CEO of Innovacorp, in a release published on Innovacorp's website yesterday. "We wanted to energize innovative entrepreneurs in western Nova Scotia. We were absolutely thrilled with the overall buzz in the community about the opportunity and the submissions we received." "We are very excited to have Midgard chosen as a winner of this year's Spark West competition," says Midgard President, Joy Hillier. "We believe our company has a tremendous opportunity to not only improve the sustainability and nutrition of dogs and cats in North America but also to change the way our society looks at insects as an environmentally sustainable and healthy food source in the future." Crickets as an alternative source of protein meet a number of nutritional requirements for both people and pets as well as being substantially more sustainable than traditional protein sources. They require less space, consume less water, and are more efficient at converting feed to protein than chicken or cattle. They also provide an easily digestible protein and a complete source of essential amino acids, as well as providing a variety of other health-supporting nutrients like calcium, omega-3 fatty acids, and the prebiotic fibre chitin. The award for Midgard comes with a $45,000 cash prize, the highest dollar amount awarded by Spark West, that will be used to expand the Company's production capacity at its current facility in Windsor, Nova Scotia. The Company already has plans to establish a second facility for research and development in association with Perennia in Bible Hill, Nova Scotia. Perennia is a non-profit corporation dedicated to helping the province's farmers, fishers and food processors prosper. "One of the great things about crickets is that they reproduce and mature very rapidly. With the financial award from Spark West, we'll be able to increase our production from one million to four million crickets every six weeks," says Hillier. Midgard Insect Farm Inc. is a Nova Scotia-based cultivator of crickets as a sustainable food source. It focuses on the production of cricket meal for wholesale to the pet food industry where there is growing demand for alternative proteins. In addition, Midgard is a leader in research into the developing science of cricket production and continually seeks to improve both the quality of its cricket meal and farming practices. It was founded in February 2016 and is operated by President Joy Hillier, a graduate of Dalhousie University's Agricultural College.
Goudar G.,Agricultural College |
Alagawadi A.R.,Agricultural College
Journal of Biopesticides | Year: 2012
A laboratory experiment was carried out to isolate and study the effect of different concentrations of Bacillus thuringiensis (Bt) crude protein on Diamond back moth (Plutella xylostella). Crude protein from thirteen Bt isolates was extracted and used at different concentrations viz., 100, 250, 500, 750, 1000 and 2000 ppm for bioassay against third instar larvae of P. xylostella. The per cent mortality was recorded after 24, 48 and 72 hrs of treatment. A cumulative mortality of 100 per cent was recorded by three isolates viz., UK-13C, UK-762D, UK-25A as well as by the reference strain HD1, followed by UK-52A, UDP-420B, DK-45B and DK-6B (93.00, 86.67, 86.67 and 83.33 respectively) at 2000 ppm after 72 hrs. The crude protein of other isolates caused larval mortality in the range of 66.67 to 80.00 per cent at 2000 ppm after 72 hrs. No larval death was observed in the control. Irrespective of the crude protein concentration, the larval mortality was highest on third day, followed by second day. ©JBiopest.